The healthcare sector has surged 17.4% in six months, outpacing the S&P 500. While demographic trends fuel long-term growth, regulatory hurdles and valuation concerns demand selective investing. We analyze one company built for decades of returns and two where investors should tread carefully.
While Roth accounts dominate the retirement planning conversation, a closer look at current tax laws and long-term income strategies reveals a compelling case for prioritizing pre-tax contributions. We examine the data with an expert and explore what gold's historical returns tell us about diversification.
Chemed Corporation (NYSE: CHE) has seen its share price soften recently, reigniting investor debate over whether the healthcare services provider is now undervalued. With the stock trading around $430, a significant gap exists against some fair value estimates, even as operational challenges in its VITAS and Roto-Rooter segments loom.
Shares of The Pennant Group (PNTG) have climbed 15% in recent months, yet remain below yearly highs. With a P/E ratio significantly above the industry average, analysts are divided on whether the stock's growth prospects justify its premium valuation.
Amid corporate restructuring fears, a professional with a substantial nest egg but no home equity grapples with the daunting math of early retirement, soaring healthcare costs, and an uncertain housing market.
